AUA

"Because we don't have calibration data on Black, or Hispanic, or Asian men in many of these risk tools, we don't know the impact of these tools as screening tests," says Adam Murphy, MD, MBA, MSCI.

"The most important thing for transgender women and their health care providers to remember is that prostate cancer screening shouldn’t be neglected," said Stephen J. Freedland, MD.

Treatment with the Optilume BPH System resulted in significant, immediate symptomatic and functional improvements in patients with BPH, according to 12-month data from the PINNACLE study.

“The ARAMIS Rollover Study extended the duration of darolutamide treatment and demonstrated the long-term safety of darolutamide in patients with [nonmetastatic CRPC],” said Neal D. Shore, MD.

“The combination of sintilimab and axitinib had a manageable safety profile and achieved a promising tumor response rate in patient with advanced FH-deficient RCC,” said Xingming Zhang.

Data from the retrospective DEAR study linked darolutamide to lower rates of discontinuation and progression to metastatic disease vs enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

"At our institution, we used a [quality improvement] protocol to first decrease overall antibiotic duration from the more standard 30 days, and then we further decreased it along with ureteral stent decrease,” says Jessica Wenzel, MD, MPH.

“This is a pivotal phase 3 trial that I think is going to be practice changing to the urology community,” said Brian Shuch, MD.

"The hazard ratio was 0.42, which is a 58% reduction of an MFS event in favor of the combination arm," says Neal D. Shore, MD, FACS.

Adding apalutamide to ADT with or without abiraterone acetate/prednisone significantly prolonged PSA PFS in men with biochemically relapsed prostate cancer, according to extended follow-up from the phase 3 PRESTO study.

"PRP does not seem to be effective in treating men with erectile dysfunction, at least as a monotherapy,” said Ranjith Ramasamy, MD.

“Zenflow is a novel minimally invasive surgical therapy that delivers a nitinol device into the prostatic urethra displacing the lateral lobes for improved urinary flow,” explained Dean Elterman, MD.

"We found that in the 25-patient pilot study that we did, that the accuracy was about 98% of what a standard sequencer would offer," says Deepak Kapoor, MD.

Beyond demonstrating clinical activity, pembrolizumab was safe and tolerable in this patient population.

“These results further support nivolumab as a standard of care for high-risk MIUC and MIBC after radical resection,” said Matthew Milowsky, MD.

The novel intravesical chemotherapy delivery system TAR-200 elicited complete responses in nearly three-fourths of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.

The update was presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

Single-dose URO-902 appeared to be safe and effective in treating women with overactive bladder and urge urinary incontinence, according to the final analysis of a phase 2a trial.

"Among the 76 men–who had an average age of about 70 and a PSA value of 4.4–up to 99% of them were able to find recurrent cancers," says Brian Helfand, MD, PhD.

The patients’ preference for vibegron could be depending on the better efficacy for urgency incontinence, said Naoki Wada, PhD.

“We looked at safety issues within 12 months after the implantation, and they were minor—some pain problems, some wound-healing problems, but no serious adverse events,” said John Heesakkers, MD, PhD.

The results may help guide the decision between a partial and radical nephrectomy in patients with stage T1b to T2 renal cell carcinoma.

“What we found is that hypertension is an independent risk factor for worsened survival outcomes and mortality outcomes across the board on multivariable and Kaplan Meier analysis,” said Sohail Dhanji, MD.

The results provide further evidence of the “obesity paradox” in patients with renal cell carcinoma.

Investigators retrospectively studied patients with Peyronie disease and diabetes mellitus between 2007 and 2022.

"What we noticed is that even though it's not in the NCCN guidelines, a lot of urologists are using oral Relugolix in combination with other prostate cancer medications in similar numbers to the injectables," says Jason M. Hafron, MD.

The 3- and 5-year MFS rates for those treated with enzalutamide plus leuprolide were 92.9% and 87.3%, respectively, compared with 83.5% and 71.4% for those given leuprolide alone.

The median time to PSA0.2 was 3.5 months in the apalutamide group, 4.4 months in the enzalutamide cohort, and 7.1 months in the abiraterone acetate group.

The deep PSA responses with the darolutamide regimen were found to be correlated with improved overall survival and a prolonged time to PSA progression.

The overall survival benefit of darolutamide in the North American population as a whole was also specifically observed in Black/African American patients.